Intravenous Ketorolac for Postoperative Pain in Percutaneous Nephrolithotomy

Mayo Clinic

Status and phase: Completed; Phase 4

Conditions: Renal Calculus; Kidney Stones

Treatments: Drug: Ketorolac; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT00765128

08-000747 PNL

Details and patient eligibility

About

The purpose of this study is to determine whether continuous intravenous ketorolac infusion reduces pain in patients who are having percutaneous nephrolithotomy for kidney stone disease.

Enrollment: 17 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients undergoing percutaneous nephrolithotomy for kidney stone disease

Exclusion criteria

• History of nonsteroidal antiinflammatory drug allergy
• Asthma
• History of long-term opioid use
• Intraoperative blood loss greater than 300 mL
• Postoperative hemodynamic instability
• Active peptic ulcer disease
• Advanced renal impairment (Creatinine > 2.0 mg/dL)
• Bleeding diathesis
• Current use of probenecid
• Pregnancy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

17 participants in 2 patient groups, including a placebo group

Ketorolac

Experimental group

Description:

90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.

Treatment:

Drug: Ketorolac

Placebo

Placebo Comparator group

Description:

1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.

Treatment:

Drug: Placebo